COSETTE Company Profile

✉ Email this page to a colleague

COSETTE has one hundred and twenty-two approved drugs.

There are five US patents protecting COSETTE drugs.

There are seventy-six patent family members on COSETTE drugs in twenty-six countries and ninety-two supplementary protection certificates in fourteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	CALCIPOTRIENE	calcipotriene	SOLUTION;TOPICAL	078468-001	Mar 24, 2011	AT	RX	No	Yes		⤷ Sign Up				⤷ Sign Up
Cosette	FLUOCINONIDE	fluocinonide	SOLUTION;TOPICAL	071535-001	Dec 2, 1988		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Cosette	HYDROCORTISONE AND ACETIC ACID	acetic acid, glacial; hydrocortisone	SOLUTION/DROPS;OTIC	040609-001	Feb 6, 2006	AT	RX	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-005	Jun 5, 2003	5,616,599*PED	⤷ Sign Up
Cosette	AZOR	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	022100-001	Sep 26, 2007	5,616,599*PED	⤷ Sign Up
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-003	Jun 5, 2003	5,616,599*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Powder for Oral Suspension	1.875 g/Packet and 3.75 g/Packet	➤ Subscribe	2010-04-09
➤ Subscribe	Tablets	5 mg/20 mg and 10 mg/40 mg	➤ Subscribe	2008-02-11
➤ Subscribe	Tablets	5 mg, 20 mg and 40 mg	➤ Subscribe	2006-04-25
➤ Subscribe	Tablets	40 mg/12.5 mg and 40 mg/25 mL	➤ Subscribe	2007-02-15
➤ Subscribe	Tablets	625 mg	➤ Subscribe	2009-07-01
➤ Subscribe	Capsules	30 mg	➤ Subscribe	2009-02-27
➤ Subscribe	Tablets	10 mg/20 mg and 5 mg/40 mg	➤ Subscribe	2008-03-31
➤ Subscribe	Tablets	20 mg/12.5 mg	➤ Subscribe	2007-05-11
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2013-07-10

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	21C1020	France	⤷ Sign Up	PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435024	2190014-7	Sweden	⤷ Sign Up	PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210
1539166	SPC/GB13/070	United Kingdom	⤷ Sign Up	PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.